Jean Francois Formela - Jun 14, 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: Director
Signature: /s/Ommer Chohan, Attorney-In-Fact
Stock symbol: NTLA
Transactions as of: Jun 14, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/16/2022, 06:33 PM
Previous filing: Jun 13, 2022
Next filing: Jun 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+5.2K	+248.19%	$0.00	7.29K	Jun 14, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Award	$0	+7.69K		$0.00	7.69K	Jun 14, 2022	Common Stock	7.69K	$38.49	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
F3	The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.